Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer

Next Previous
Trial Profile

A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 577
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 22 May 2025 According to Bristol Myers Squibb media release, data from this study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held on Saturday, May 31, 2025 in Chicago, Illinois.
  • 09 Nov 2022 Results of cost effective analysis of adjuvant nivolumab versus current clinical practice (surveillance) in patients with EC/GEJC who have residual disease after neoadjuvant chemoradiotherapy followed by complete resection presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 18 Mar 2022 Results of exposure response analyses of nivolumab as adjuvant treatment in patients with esophageal cancer or gastroesophageal junction cancer presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top